Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market to Reach US$ 6.28 Billion by 2033, Driven by Rising Disease Awareness

The global Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Market reached USD 2.48 billion in 2025 and is expected to reach USD 6.28 billion by 2033, growing at a CAGR of 8.6% during the forecast period from 2026 to 2033. The market is gaining momentum as bronchiectasis is increasingly recognized as a chronic respiratory condition requiring long-term disease management rather than episodic treatment. Rising diagnosis among aging populations, recurrent respiratory infections, increasing use of high-resolution CT for disease identification, and growing awareness of bronchiectasis are expanding the addressable patient population. Demand is particularly increasing for airway-clearance therapies, inhaled antibiotics, bronchodilators, mucolytics, and long-term infection management, creating significant opportunities across pharmaceutical and respiratory-care markets.

A major growth opportunity is emerging around targeted therapies and precision management of chronic airway infection and inflammation. Pharmaceutical companies are advancing inhaled and anti-inflammatory treatments, while medical technology providers are developing portable airway-clearance and respiratory support solutions that can improve adherence to long-term therapy. The increasing clinical focus on preventing exacerbations and reducing hospitalizations is also encouraging investment in therapies that can provide sustained disease control. As diagnosis improves and treatment moves toward personalized, long-term respiratory management, the NCFB treatment market is positioned for strong expansion, particularly across populations with recurrent infections and complex chronic respiratory conditions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/non-cystic-fibrosis-bronchiectasis-treatment-market?sai-v

Recent Developments
July 2026: Insmed continued the commercial expansion of BRINSUPRI (brensocatib) following its U.S. approval as the first treatment specifically indicated for NCFB. The therapy is being adopted across the North American market, strengthening the shift toward targeted treatment of neutrophil-driven airway inflammation.

June 2026: Boehringer Ingelheim advanced BI 1291583 (brensocatib/verducatib) through the Phase III AIRTIVITY program for bronchiectasis, evaluating long-term inhibition of dipeptidyl peptidase 1 (DPP1) to reduce pulmonary exacerbations. The program is strengthening the emerging pipeline of targeted anti-inflammatory therapies across Europe and other international markets.

May 2026: Insmed continued expanding access to BRINSUPRI across international markets following the European authorization of the therapy for patients aged 12 years and older with NCFB and recurrent exacerbations. The development is increasing availability of targeted NCFB treatment across Europe and complementing its U.S. launch.

April 2026: Renovion continued development of ARINA-1 (RVN-301), an investigational nebulized therapy for NCFB. The program focuses on improving mucus clearance and addressing airway inflammation, supporting the development of inhaled treatment approaches for patients with persistent mucus and cough.

March 2026: The American Thoracic Society (ATS) highlighted the growing clinical impact of newly available targeted bronchiectasis therapy and the expanding pipeline of treatments at its 2026 conference. The development landscape is increasingly focused on reducing exacerbations and targeting underlying neutrophilic inflammation, supporting innovation across North America and Europe.

Key Players
Insmed Incorporated | Merck & Co., Inc. | Baxter International Inc. | Pfizer Inc. | Johari Digital Healthcare Ltd. | HMS Medical Systems | Ralington Pharma LLP | AdvaCare Pharma | Life Care Systems | VIVAN Life Sciences | Others

Key Highlights
Insmed Incorporated - Holds a 28.6% share, driven by its focus on bronchiectasis therapies, advanced inhaled drug delivery technologies, and development of targeted treatments for chronic respiratory diseases.

Merck & Co., Inc. - Holds a 16.8% share, supported by its broad respiratory and infectious disease portfolio, clinical research capabilities, and global pharmaceutical infrastructure.

Baxter International Inc. - Holds a 12.4% share, strengthened by its respiratory care technologies, hospital solutions, drug delivery systems, and critical care product portfolio.

Pfizer Inc. - Holds a 10.7% share, fueled by its respiratory and infectious disease therapies, extensive clinical development capabilities, and global healthcare distribution network.

Johari Digital Healthcare Ltd. - Holds a 7.2% share, driven by its respiratory healthcare technologies, medical device manufacturing capabilities, and focus on advanced drug delivery solutions.

HMS Medical Systems - Holds a 5.8% share, supported by its respiratory care equipment, medical devices, and healthcare solutions for chronic respiratory disease management.

Ralington Pharma LLP - Holds a 4.9% share, strengthened by its pharmaceutical portfolio, respiratory medicines, and expanding presence in emerging healthcare markets.

AdvaCare Pharma - Holds a 4.1% share, driven by its broad pharmaceutical and medical device portfolio, respiratory care products, and international distribution network.

Life Care Systems - Holds a 3.2% share, supported by its respiratory care equipment, medical devices, and healthcare solutions focused on improving chronic disease management.

VIVAN Life Sciences - Holds a 2.7% share, fueled by its pharmaceutical products, respiratory healthcare offerings, and growing presence in specialty treatment markets.

Others - Hold a combined 3.6% share, comprising regional pharmaceutical manufacturers, respiratory device companies, specialty drug developers, and emerging healthcare providers focused on improving diagnosis and treatment of non-cystic fibrosis bronchiectasis.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=non-cystic-fibrosis-bronchiectasis-treatment-market?sai-v

Market Drivers
Rising NCFB prevalence, improved diagnosis, and increasing awareness of chronic respiratory diseases are driving market growth.

Growing adoption of long-term antibiotics, bronchodilators, mucolytics, airway-clearance therapies, and anti-inflammatory treatments is supporting demand.

Increasing focus on targeted therapies and personalized respiratory care is accelerating treatment innovation.

Market Opportunities
Growing demand for disease-modifying therapies and novel anti-inflammatory treatments is creating new opportunities.

Increasing investments in inhaled therapies, airway-clearance technologies, and personalized treatment approaches are expanding market potential.

August 2026: Insmed reported US$309.2 million in Brinsupri revenue for Q2 2026 and raised its 2026 Brinsupri revenue outlook to US$1.25-1.40 billion, reflecting strong uptake in NCFB treatment.

Expanding clinical research, regulatory approvals, and strategic collaborations are strengthening the treatment pipeline.

Industry Developments
Targeted anti-inflammatory therapies, inhaled drug delivery, and advanced airway-clearance technologies are transforming NCFB treatment.

FDA approval of Insmed's brensocatib, marketed as Brinsupri, marked a major advancement as the first approved treatment specifically for NCFB.

Brinsupri's strong commercial performance led Insmed to increase its 2026 revenue guidance.

Clinical trials, product launches, regulatory activities, and pipeline investments are strengthening competition.

Regional Insights
North America 39.0% share: Leads the market with a 39.0% share due to advanced respiratory-care infrastructure, high disease awareness, strong pharmaceutical presence, and rapid adoption of novel therapies.

Europe 29.2% share: Holds a 29.2% share, supported by established respiratory-care systems, increasing diagnosis, clinical research, and adoption of advanced treatments.

Asia Pacific 23.1% share: Fastest-growing region with a 23.1% share, driven by rising respiratory disease prevalence, improving diagnostic capabilities, expanding healthcare infrastructure, and growing pharmaceutical investments.

Latin America 4.7% share: Accounts for a 4.7% share, supported by improving access to respiratory care, increasing disease awareness, and expanding treatment availability.

Middle East & Africa 4.0% share: Represents a 4.0% share, driven by healthcare modernization, improving diagnosis, and increasing access to advanced respiratory therapies.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/non-cystic-fibrosis-bronchiectasis-treatment-market?sai-v

Key Segments
➥ By Treatment Type

Physiotherapy: Represents a significant segment, driven by the increasing adoption of respiratory physiotherapy techniques to improve lung function, mobilize airway secretions, and reduce recurrent respiratory complications.

Vaccination: Represents a growing segment, supported by increasing emphasis on preventing respiratory infections that can contribute to disease exacerbations and worsening of bronchiectasis.

Airway Clearance: Represents the dominant segment, driven by the central role of airway clearance techniques in removing excessive mucus, reducing infection risk, and improving respiratory function among NCFB patients.

Pulmonary Rehabilitation: Represents a significant segment, fueled by increasing use of structured rehabilitation programs to improve exercise capacity, respiratory health, and quality of life.

Antibiotics: Represents a major segment, supported by the high incidence of recurrent bacterial infections and exacerbations requiring antimicrobial treatment in NCFB patients.

Macrolides: Represents a significant segment, driven by their use in reducing recurrent exacerbations and managing chronic airway inflammation in selected patients with bronchiectasis.

Oral Steroids: Represents a moderate segment, supported by their use in selected cases involving significant airway inflammation and associated respiratory conditions.

Bronchodilators: Represents a growing segment, fueled by increasing use among patients experiencing airflow limitation, breathlessness, and coexisting obstructive airway conditions.

Others: Represents a moderate segment, supported by expanding adoption of mucolytics, inhaled therapies, anti-inflammatory treatments, and emerging therapeutic approaches for NCFB management.

➥ By Route of Administration

Oral: Represents the dominant segment, driven by widespread use of oral antibiotics, macrolides, corticosteroids, and other supportive therapies that offer convenient administration for long-term disease management.

Nasal: Represents a growing segment, supported by increasing use of nasal and inhaled delivery approaches to improve localized respiratory treatment and symptom management.

Intravenous: Represents a significant segment, fueled by the use of intravenous antibiotics and other therapies for patients experiencing severe exacerbations or infections requiring hospital-based treatment.

Others: Represents a moderate segment, supported by increasing adoption of inhaled, nebulized, and other localized drug delivery routes for improving treatment effectiveness and patient convenience.

➥ By Sales Channel

Distribution Channel: Represents a significant segment, supported by the role of pharmaceutical distributors, specialty distributors, and medical supply networks in ensuring consistent availability of antibiotics, respiratory devices, and supportive treatments.

End-User: Represents the dominant segment, driven by direct procurement and utilization of NCFB treatments across hospitals, specialty clinics, pharmacies, and other healthcare facilities involved in bronchiectasis management.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.